Therefore, we set out to test the impact of prophylactic and therapeutic vaccination against ADAM12 on tumor desmoplasia in preclinical models of pancreatic ductal adenocarcinoma. This evidence concerns the gene ADAM12 and pancreatic ductal adenocarcinoma.